Payment overview · 2025
General Payments
$250.55
14 reported records · 7 companies
Healthcare provider profile · identity verified
Bobby G Jones, DO
Allopathic & Osteopathic Physicians|Family Medicine · SEMINARY, MS · NPI 1205940095
Verified facts
What the public records show
CMS Open Payments records show Bobby G Jones, DO received $250.55 in general payments during 2025 across 14 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 27.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $69.46 | 27.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.29 | 20.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.27 | 17.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.05 | 13.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.16 | 7.2% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.86 | 7.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.46 | 6.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $250.55 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $69.46 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $51.29 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $51.29 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $44.27 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.27 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.05 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 117 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
84 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
117 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 455 | 111 |
| Atorvastatin Calcium | Atorvastatin Calcium | 437 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 416 | 101 |
| Gabapentin | Gabapentin | 360 | 88 |
| Omeprazole | Omeprazole | 347 | 83 |
| Trazodone Hcl | Trazodone Hcl | 290 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 266 | 62 |
| Valsartan | Valsartan | 226 | 54 |
| Metformin Hcl | Metformin Hcl | 203 | 44 |
| Carvedilol | Carvedilol | 200 | 40 |
| Sertraline Hcl | Sertraline Hcl | 200 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 194 | 39 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 183 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 174 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 168 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 168 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 166 | 59 |
| Lisinopril | Lisinopril | 163 | 42 |
| Meloxicam | Meloxicam | 160 | 54 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 156 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 156 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 134 | 30 |
| Prednisone | Prednisone | 133 | 95 |
| Metformin Hcl Er | Metformin Hcl | 131 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 126 | 53 |
| Spironolactone | Spironolactone | 118 | 28 |
| Ozempic | Semaglutide | 117 | 22 |
| Furosemide | Furosemide | 116 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 114 | 31 |
| Glimepiride | Glimepiride | 113 | 30 |
| Tramadol Hcl | Tramadol Hcl | 110 | 16 |
| Montelukast Sodium | Montelukast Sodium | 109 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 99 | 32 |
| Losartan Potassium | Losartan Potassium | 97 | 26 |
| Celecoxib | Celecoxib | 96 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 93 | 12 |
| Allopurinol | Allopurinol | 87 | 19 |
| Simvastatin | Simvastatin | 87 | 23 |
| Pregabalin | Pregabalin | 84 | 17 |
| Synthroid | Levothyroxine Sodium | 84 | 13 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 81 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 78 | 66 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 19 |
| Jardiance | Empagliflozin | 67 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 19 |
| Azithromycin | Azithromycin | 66 | 61 |
| Oxybutynin Chloride | Oxybutynin Chloride | 65 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 17 |
| Januvia | Sitagliptin Phosphate | 63 | 13 |
| Irbesartan | Irbesartan | 62 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 61 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 59 | 18 |
| Buspirone Hcl | Buspirone Hcl | 58 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 13 |
| Potassium Chloride | Potassium Chloride | 58 | 16 |
| Bupropion Xl | Bupropion Hcl | 55 | 11 |
| Famotidine | Famotidine | 55 | 17 |
| Warfarin Sodium | Warfarin Sodium | 53 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 51 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 13 |
| Donepezil Hcl | Donepezil Hcl | 48 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 40 |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 37 |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | 12 |
| Eliquis | Apixaban | 38 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 17 |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 23 |
| Cephalexin | Cephalexin | 28 | 27 |
| Mometasone Furoate | Mometasone Furoate | 28 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 27 | suppressed |
| Repaglinide | Repaglinide | 27 | suppressed |
| Cefdinir | Cefdinir | 24 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 13 |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Indapamide | Indapamide | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Sulindac | Sulindac | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $250.55 · 14 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, VRAYLAR, XIFAXAN, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error